Molecular Partners (NASDAQ:MOLN) AG (NASDAQ: MOLN) is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that specializes in the discovery and development of DARPin® (Designed Ankyrin Repeat Protein) therapeutics. DARPin molecules are engineered protein scaffolds designed to mimic and improve upon natural antibodies in terms of stability, specificity and manufacturability. The company applies this proprietary platform to develop multi-specific, targeted therapies for oncology, ophthalmology and immuno-oncology indications.
Since its founding in 2004, Molecular Partners has advanced a diversified pipeline of product candidates through preclinical and clinical stages. Lead programs include abicipar pegol, a long-acting anti-VEGF DARPin currently in late-stage development for wet age-related macular degeneration, and MP0250, a bispecific DARPin targeting VEGF and HGF for multiple myeloma and solid tumors. Additional early-stage candidates explore immuno-oncology approaches, such as T-cell engaging DARPin molecules designed to recruit and activate the patient’s own immune system against tumors.
Molecular Partners maintains strategic partnerships with major global biopharmaceutical companies to co-develop and commercialize DARPin-based treatments. Collaborations include an ophthalmology agreement with AbbVie (following its acquisition of Allergan), as well as oncology partnerships with AbbVie and other research organizations. Manufacturing operations are conducted at state-of-the-art facilities in Switzerland, and the company has established a clinical development presence in the United States to support ongoing and future trials.
The company’s leadership team combines seasoned biotechnology entrepreneurs, academic scientists and experienced drug developers. Chief Executive Officer Dr. Michael Hennig guides corporate strategy and operations, while a senior management team oversees research, development and global partnerships. Under this leadership, Molecular Partners remains focused on advancing its DARPin pipeline toward regulatory milestones and delivering innovative therapies to patients worldwide.
